Почетна › Trostruko negativni rak dojke › Тексас › San Antonio
Kliničke studije za Trostruko negativni rak dojke u gradu San Antonio, TX
24 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u gradu San Antonio i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- UT Health San Antonio's Mays Cancer Center, San Antonio
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Тражи се учесникФаза 3
- Texas Oncology - San Antonio ( Site 8001), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Тражи се учесникФаза 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Тражи се учесникФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Тражи се учесникФаза 1
- START San Antonio, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- START San Antonio, San Antonio
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Тражи се учесникФаза 3
- Mays Cancer Center ( Site 0122), San Antonio
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Тражи се учесникФаза 3
- Texas Oncology, San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- NEXT Oncology, San Antonio
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Тражи се учесникФаза 1
- Univ Texas HSC San Antonio /ID# 257708, San Antonio
- South Texas Accelerated Research Therapeutics /ID# 260404, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Тражи се учесникФаза 1/2
- NEXT Oncology, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Clinical Trial Site, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Research Site, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- NEXT Oncology - San Antonio, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Тражи се учесникФаза 1
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- START San Antonio, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Тражи се учесникФаза 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Тражи се учесникФаза 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- NEXT Oncology, San Antonio
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Тражи се учесникФаза 1
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Тражи се учесникФаза 1
- Dren Investigational Site, San Antonio
Studije za Trostruko negativni rak dojke u drugim gradovima
- Houston, TX42 студија
- New York City, NY33 студија
- Nashville, TN28 студија
- Los Angeles, CA27 студија
- Boston, MA24 студија
- Arlington, VA21 студија
- St. Louis, MO21 студија
- Atlanta, GA19 студија
- Dallas, TX18 студија
- New Haven, CT16 студија
- Grand Rapids, MI16 студија
- Chicago, IL16 студија
Ostale studije u gradu San Antonio
- Немалоклетни карцином плућа60 студија
- Рак дојке45 студија
- Метастатски карцином44 студија
- Колоректални карцином43 студија
- Рак (све врсте)41 студија
- Гојазност39 студија
- Dijabetes tipa 237 студија
- Гојазност34 студија
- Рак јајника33 студија
- Рак панкреаса33 студија
- Рак плућа27 студија
- Рак простате27 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.